FR2968995B1 - Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage - Google Patents

Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage

Info

Publication number
FR2968995B1
FR2968995B1 FR1060655A FR1060655A FR2968995B1 FR 2968995 B1 FR2968995 B1 FR 2968995B1 FR 1060655 A FR1060655 A FR 1060655A FR 1060655 A FR1060655 A FR 1060655A FR 2968995 B1 FR2968995 B1 FR 2968995B1
Authority
FR
France
Prior art keywords
oral administration
pharmaceutical composition
prevent measurement
present
prevent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1060655A
Other languages
English (en)
Other versions
FR2968995A1 (fr
Inventor
Annick Martinez
Olivier Rougeot
Yoshikatsu Yaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1060655A priority Critical patent/FR2968995B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to PCT/EP2011/072933 priority patent/WO2012080408A1/fr
Priority to EP11799420.2A priority patent/EP2651391B1/fr
Priority to JP2013543787A priority patent/JP5960159B2/ja
Priority to ARP110104692A priority patent/AR084299A1/es
Priority to TW100146612A priority patent/TWI538698B/zh
Publication of FR2968995A1 publication Critical patent/FR2968995A1/fr
Application granted granted Critical
Publication of FR2968995B1 publication Critical patent/FR2968995B1/fr
Priority to US13/918,149 priority patent/US20130280326A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1060655A 2010-12-16 2010-12-16 Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage Expired - Fee Related FR2968995B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1060655A FR2968995B1 (fr) 2010-12-16 2010-12-16 Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
EP11799420.2A EP2651391B1 (fr) 2010-12-16 2011-12-15 Composition pharmaceutique destinee a eviter l'abus par des tiers
JP2013543787A JP5960159B2 (ja) 2010-12-16 2011-12-15 誤用を防止することを目的とする経口投与用医薬組成物
ARP110104692A AR084299A1 (es) 2010-12-16 2011-12-15 Composicion farmaceutica para una administracion por via oral destinada a evitar el mal uso
PCT/EP2011/072933 WO2012080408A1 (fr) 2010-12-16 2011-12-15 Composition pharmaceutique pour une administration orale destinée à empêcher un mauvais usage
TW100146612A TWI538698B (zh) 2010-12-16 2011-12-15 防止誤用之口服醫藥組合物
US13/918,149 US20130280326A1 (en) 2010-12-16 2013-06-14 Pharmaceutical composition for oral administration intended to prevent misuse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1060655A FR2968995B1 (fr) 2010-12-16 2010-12-16 Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage

Publications (2)

Publication Number Publication Date
FR2968995A1 FR2968995A1 (fr) 2012-06-22
FR2968995B1 true FR2968995B1 (fr) 2013-03-22

Family

ID=44269233

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1060655A Expired - Fee Related FR2968995B1 (fr) 2010-12-16 2010-12-16 Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage

Country Status (7)

Country Link
US (1) US20130280326A1 (fr)
EP (1) EP2651391B1 (fr)
JP (1) JP5960159B2 (fr)
AR (1) AR084299A1 (fr)
FR (1) FR2968995B1 (fr)
TW (1) TWI538698B (fr)
WO (1) WO2012080408A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2943728C (fr) * 2014-03-26 2020-03-24 Sun Pharma Advanced Research Company Ltd. Forme galenique solide de matrice biphasique a liberation immediate et dissuasive d'abus
FR3027802B1 (fr) * 2014-10-31 2018-03-02 Ethypharm Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705691A (en) * 1985-11-18 1987-11-10 The Procter & Gamble Co. Beverage opacifier
GB2279961A (en) * 1993-06-22 1995-01-18 Ici Plc Paint containing white opacifier
EP1005863A1 (fr) * 1998-12-04 2000-06-07 Synthelabo Formes galeniques a liberation controlee contenant un hypnotique a activite courte ou un sel de ce compose
FR2787715B1 (fr) * 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
EP1064937A1 (fr) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Formes pharmaceutiques à liberation controllée comprenant un hypnotique à courte duree ou une des ses sels
US6759073B2 (en) * 2001-07-02 2004-07-06 The Procter & Gamble Co. Compositions and methods for stabilization and enhanced viscosity
IL160855A0 (en) * 2001-09-26 2004-08-31 Pharmacia Corp Intraorally disintegrating valdecoxib compositions
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
FR2848855B1 (fr) 2002-12-23 2005-02-11 Aventis Pharma Sa Compositions pour administration orale de principes actifs necessitant un masquage du gout
US20070196476A1 (en) * 2004-04-30 2007-08-23 Withiam Michael C Rapidly dissolving tablets comprising low surface area titanium dioxide
JP2011506279A (ja) * 2007-12-08 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 経口で分散可能な錠剤
JP2009179603A (ja) * 2008-01-31 2009-08-13 Kyorin Pharmaceut Co Ltd 口腔内速崩壊性錠剤及びその製造方法
NZ594207A (en) * 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol

Also Published As

Publication number Publication date
JP5960159B2 (ja) 2016-08-02
TWI538698B (zh) 2016-06-21
WO2012080408A1 (fr) 2012-06-21
JP2013545784A (ja) 2013-12-26
US20130280326A1 (en) 2013-10-24
TW201306879A (zh) 2013-02-16
EP2651391B1 (fr) 2019-01-23
FR2968995A1 (fr) 2012-06-22
AR084299A1 (es) 2013-05-08
EP2651391A1 (fr) 2013-10-23

Similar Documents

Publication Publication Date Title
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA201490223A1 (ru) Составы на основе дарунавира
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX347373B (es) Soluciones anti-inflamatorias estables para inyección.
EA201270728A1 (ru) Пуриновые соединения
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
MA34709B1 (fr) Compositions pharmaceutiques
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола
FR2968995B1 (fr) Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

ST Notification of lapse

Effective date: 20220808